We are a very active member of the Children's
Oncology Group Phase I and Phase II - III consortiums, offering families access to a wide range of clinical trials designed to find new treatments for childhood cancers.
We are the only Children's
Oncology Group Phase I Consortium member in the state of Michigan, which means that we offer unique studies unavailable at other hospitals in Michigan.
Not exact matches
In the
Phase II clinical trial, Dr. Miller and colleagues in the National Cancer Institute - supported Gynecologic
Oncology Group found that in patients who had not received prior chemotherapy, the combination cocktail had a 31 percent response rate for up to 7 months, and an overall survival of 12 months.
The
phase 2 randomized clinical trial was conducted by the Eastern Cooperative
Oncology Group, enrolling 245 patients with stage 3 or stage 4 metastatic melanoma who had been treated with other drugs.
Based on these results, two
phase 3 trials are being planned for platinum - sensitive and platinum - resistant ovarian cancer patients by one of NCI's new National Cancer Trial Network
Groups, the NRG Oncology Group (formerly 3 cooperative groups: the National Surgical Adjuvant Breast and Bowel Project (NSABP), the Radiation Therapy Oncology Group (RTOG), and the Gynecologic Oncology Group
Groups, the NRG
Oncology Group (formerly 3 cooperative
groups: the National Surgical Adjuvant Breast and Bowel Project (NSABP), the Radiation Therapy Oncology Group (RTOG), and the Gynecologic Oncology Group
groups: the National Surgical Adjuvant Breast and Bowel Project (NSABP), the Radiation Therapy
Oncology Group (RTOG), and the Gynecologic
Oncology Group (GOG).
This
phase III trial was performed in collaboration with European Network of Gynaecological
Oncology Trial
groups (ENGOT).
The
Phase III clinical trial, conducted by the Radiation Therapy
Oncology Group (RTOG), randomized 637 patients at multiple centers, including the University of Maryland Greenebaum Cancer Center, into two
groups.
A
phase 3 trial of whole brain radiation therapy and stereotactic radiosurgery alone versus WBRT and SRS with temozolomide or erlotinib for non-small cell lung cancer and 1 to 3 brain metastases: Radiation Therapy
Oncology Group 0320.
He is the Principal Investigator of international
Phase - II, randomized trial of Chimeric 14.18 or Temsirolimus in combination with Irinotecan / Temozolomide through Children's
Oncology Group (COG).
He is a member of the High Risk Neurobalstoma Committee of COG, institutional performance review committee for COG
Phase - I consortium and is the Principle Investigator of the Children's
Oncology Group,
Phase - I,
Phase II - III Consortium studies at C.S. Mott Children's Hospital.
We sponsor clinical trials for newly diagnosed neuroblastoma patients through the Children's
Oncology Group (COG) and, through COG and the New Approaches to Neuroblastoma Therapy Consortium, Dana - Farber / Boston Children's offers the most
Phase I clinical studies in New England for children whose disease has recurred.